{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:19:03Z","timestamp":1794507543713,"version":"4.9.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["ZIA00069"],"award-info":[{"award-number":["ZIA00069"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Ministry of Economy and Competitiveness | Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2020-117989RA-I00"],"award-info":[{"award-number":["PID2020-117989RA-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Ministry of Economy and Competitiveness | Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["RYC-2019-027371-I"],"award-info":[{"award-number":["RYC-2019-027371-I"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["RAI145211A"],"award-info":[{"award-number":["RAI145211A"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1038\/s41380-022-01673-w","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T13:05:16Z","timestamp":1656507916000},"page":"4144-4156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-0151","authenticated-orcid":false,"given":"Jordi","family":"Bonaventura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan L.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan L.","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sanchez-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruin","family":"Moaddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-8648","authenticated-orcid":false,"given":"Panos","family":"Zanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig J.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0624-962X","authenticated-orcid":false,"given":"David R.","family":"Sibley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0398-4917","authenticated-orcid":false,"given":"Michael","family":"Michaelides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"1673_CR1","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","volume":"101","author":"JH Krystal","year":"2019","unstructured":"Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: a paradigm shift for depression research and treatment. Neuron 2019;101:774\u20138.","journal-title":"Neuron"},{"key":"1673_CR2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jad.2020.09.071","volume":"278","author":"A Bahji","year":"2021","unstructured":"Bahji A, Vazquez GH, Zarate CA. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2021;278:542\u201355.","journal-title":"J Affect Disord"},{"key":"1673_CR3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1176\/appi.ajp.2019.19040423","volume":"176","author":"AF Schatzberg","year":"2019","unstructured":"Schatzberg AF. A word to the wise about intranasal esketamine. Am J Psychiatry. 2019;176:422\u20134.","journal-title":"Am J Psychiatry"},{"key":"1673_CR4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/appi.ajp.2014.13101434","volume":"171","author":"AF Schatzberg","year":"2014","unstructured":"Schatzberg AF. A word to the wise about ketamine. Am J Psychiatry. 2014;171:262\u20134.","journal-title":"Am J Psychiatry"},{"key":"1673_CR5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/YCO.0b013e3282f32408","volume":"21","author":"L Davis","year":"2008","unstructured":"Davis L, Uezato A, Newell JM, Frazier E. Major depression and comorbid substance use disorders. Curr Opin Psychiatry. 2008;21:14\u201318.","journal-title":"Curr Opin Psychiatry"},{"key":"1673_CR6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/archpsyc.64.5.566","volume":"64","author":"WM Compton","year":"2007","unstructured":"Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: Results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64:566\u201376.","journal-title":"Arch Gen Psychiatry"},{"key":"1673_CR7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","volume":"73","author":"K Hashimoto","year":"2019","unstructured":"Hashimoto K. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective. Psychiatry Clin Neurosci. 2019;73:613\u201327.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1673_CR8","doi-asserted-by":"publisher","unstructured":"Hashimoto K. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine. Biochem Pharmacol. 2020;177:113935. https:\/\/doi.org\/10.1016\/j.bcp.2020.113935.","DOI":"10.1016\/j.bcp.2020.113935"},{"key":"1673_CR9","doi-asserted-by":"publisher","unstructured":"Bonaventura J, Lam S, Carlton M, Boehm MA, Gomez JL, Sol\u00eds O, et al. Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Mol Psychiatry. 2021. https:\/\/doi.org\/10.1038\/s41380-021-01093-2.","DOI":"10.1038\/s41380-021-01093-2"},{"key":"1673_CR10","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","volume":"35","author":"LA Jelen","year":"2021","unstructured":"Jelen LA, Young AH, Stone JM. Ketamine: a tale of two enantiomers. J Psychopharmacol. 2021;35:109\u201323.","journal-title":"J Psychopharmacol"},{"key":"1673_CR11","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1111\/bph.14683","volume":"176","author":"P Zanos","year":"2019","unstructured":"Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, et al. (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. Br J Pharm. 2019;176:2573\u201392.","journal-title":"Br J Pharm"},{"key":"1673_CR12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481\u20136.","journal-title":"Nature."},{"key":"1673_CR13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","volume":"271","author":"GC Leal","year":"2021","unstructured":"Leal GC, Bandeira ID, Correia-Melo FS, Telles M, Mello RP, Vieira F, et al. Intravenous arketamine for treatment-resistant depression: open-label pilot study. Eur Arch Psychiatry Clin Neurosci. 2021;271:577\u201382.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1673_CR14","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","volume":"116","author":"EW Lumsden","year":"2019","unstructured":"Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, et al. Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function. Proc Natl Acad Sci USA. 2019;116:5160\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1673_CR15","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","volume":"116","author":"P Zanos","year":"2019","unstructured":"Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, et al. (2R,6R)-hydroxynorketamine exerts mGlu2 receptordependent antidepressant actions. Proc Natl Acad Sci USA. 2019;116:6441\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1673_CR16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","volume":"184","author":"PC Casarotto","year":"2021","unstructured":"Casarotto PC, Girych M, Fred SM, Kovaleva V, Moliner R, Enkavi G, et al. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell. 2021;184:1299\u20131313. e19.","journal-title":"Cell."},{"key":"1673_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.06.033","volume":"139","author":"D Chou","year":"2018","unstructured":"Chou D, Peng HY, Lin TB, Lai CY, Hsieh MC, Wen YC, et al. (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. Neuropharmacology. 2018;139:1\u201312.","journal-title":"Neuropharmacology"},{"key":"1673_CR18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-020-03047-0","volume":"590","author":"A Aguilar-Valles","year":"2021","unstructured":"Aguilar-Valles A, De Gregorio D, Matta-Camacho E, Eslamizade MJ, Khlaifia A, Skaleka A, et al. Antidepressant actions of ketamine engage cell-specific translation via eIF4E. Nature. 2021;590:315\u20139.","journal-title":"Nature."},{"key":"1673_CR19","doi-asserted-by":"crossref","first-page":"172973","DOI":"10.1016\/j.pbb.2020.172973","volume":"196","author":"GI Elmer","year":"2020","unstructured":"Elmer GI, Tapocik JD, Mayo CL, Zanos P, Gould TD. Ketamine metabolite (2R,6R)-hydroxynorketamine reverses behavioral despair produced by adolescent trauma. Pharm Biochem Behav. 2020;196:172973.","journal-title":"Pharm Biochem Behav"},{"key":"1673_CR20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","volume":"70","author":"P Zanos","year":"2018","unstructured":"Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: Insights into therapeutic mechanisms. Pharm Rev. 2018;70:621\u201360.","journal-title":"Pharm Rev"},{"key":"1673_CR21","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pharmrev.120.000149","volume":"73","author":"JN Highland","year":"2021","unstructured":"Highland JN, Zanos P, Riggs LM, Georgiou P, Clark SM, Morris PJ, et al. Hydroxynorketamines: Pharmacology and potential therapeutic applications. Pharm Rev. 2021;73:763\u201391.","journal-title":"Pharm Rev"},{"key":"1673_CR22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41386-019-0443-3","volume":"45","author":"LM Riggs","year":"2019","unstructured":"Riggs LM, Aracava Y, Zanos P, Fischell J, Albuquerque EX, Pereira EFR, et al. (2R,6R)-hydroxynorketamine rapidly potentiates hippocampal glutamatergic transmission through a synapse-specific presynaptic mechanism. Neuropsychopharmacol. 2019;45:426\u201336. 2019 452.","journal-title":"Neuropsychopharmacol"},{"key":"1673_CR23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1073\/pnas.1814709116","volume":"116","author":"K Fukumoto","year":"2019","unstructured":"Fukumoto K, Fogaca MV, Liu RJ, Duman C, Kato T, Li XY, et al. Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2R,6R)-hydroxynorketamine. Proc Natl Acad Sci USA. 2019;116:297\u2013302.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1673_CR24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/s41386-020-0714-z","volume":"45","author":"BK Chen","year":"2020","unstructured":"Chen BK, Luna VM, LaGamma CT, Xu X, Deng SX, Suckow RF, et al. Sex-specific neurobiological actions of prophylactic (R,S)-ketamine, (2R,6R)-hydroxynorketamine, and (2S,6S)-hydroxynorketamine. Neuropsychopharmacology 2020;45:1545\u201356.","journal-title":"Neuropsychopharmacology"},{"key":"1673_CR25","doi-asserted-by":"publisher","unstructured":"Chou D Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions. Neuropharmacology. 2020;170:108068. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108068.","DOI":"10.1016\/j.neuropharm.2020.108068"},{"key":"1673_CR26","doi-asserted-by":"crossref","first-page":"100404","DOI":"10.1016\/j.ynstr.2021.100404","volume":"15","author":"DP Herzog","year":"2021","unstructured":"Herzog DP, Perumal N, Manicam C, Treccani G, Nadig J, Rossmanith M, et al. Longitudinal CSF proteome profiling in mice to uncover the acute and sustained mechanisms of action of rapid acting antidepressant (2R,6R)-hydroxynorketamine (HNK). Neurobiol Stress. 2021;15:100404.","journal-title":"Neurobiol Stress"},{"key":"1673_CR27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269881118812095","volume":"33","author":"JN Highland","year":"2019","unstructured":"Highland JN, Morris PJ, Zanos P, Lovett J, Ghosh S, Wang AQ, et al. Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine. J Psychopharmacol. 2019;33:12\u201324.","journal-title":"J Psychopharmacol"},{"key":"1673_CR28","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.biopsych.2017.10.020","volume":"84","author":"TH Pham","year":"2018","unstructured":"Pham TH, Defaix C, Xu X, Deng SX, Fabresse N, Alvarez JC, et al. Common neurotransmission recruited in (R,S)-ketamine and (2R,6R)-hydroxynorketamine-induced sustained antidepressant-like effects. Biol Psychiatry. 2018;84:e3\u2013e6.","journal-title":"Biol Psychiatry"},{"key":"1673_CR29","doi-asserted-by":"publisher","unstructured":"Wulf HA, Browne CA, Zarate CA, Lucki I Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors. Psychopharmacology. 2022. April 2022. https:\/\/doi.org\/10.1007\/S00213-022-06118-4.","DOI":"10.1007\/S00213-022-06118-4"},{"key":"1673_CR30","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","volume":"116","author":"P Zanos","year":"2019","unstructured":"Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, et al. (2R,6R)-hydroxynorketamine exerts mGlu2 receptordependent antidepressant actions. Proc Natl Acad Sci USA. 2019;116:6441\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1673_CR31","doi-asserted-by":"publisher","unstructured":"Aleksandrova LR, Wang YT, Phillips AG. Ketamine and its metabolite, (2R,6R)-HNK, restore hippocampal LTP and long-term spatial memory in the Wistar-Kyoto rat model of depression. Mol Brain. 2020;13:92. https:\/\/doi.org\/10.1186\/s13041-020-00627-z.","DOI":"10.1186\/s13041-020-00627-z"},{"key":"1673_CR32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bbrc.2022.01.025","volume":"593","author":"WH Peng","year":"2022","unstructured":"Peng WH, Kan HW, Ho YC. Periaqueductal gray is required for controlling chronic stress-induced depression-like behavior. Biochem Biophys Res Commun. 2022;593:28\u201334.","journal-title":"Biochem Biophys Res Commun"},{"key":"1673_CR33","doi-asserted-by":"publisher","unstructured":"Ju L, Yang J, Zhu T, Liu P, Yang J. BDNF-TrkB signaling-mediated upregulation of Narp is involved in the antidepressant-like effects of (2R,6R)-hydroxynorketamine in a chronic restraint stress mouse model. BMC Psychiatry. 2022;22:182. https:\/\/doi.org\/10.1186\/s12888-022-03838-x.","DOI":"10.1186\/s12888-022-03838-x"},{"key":"1673_CR34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/NDT.S278422","volume":"17","author":"X Zhong","year":"2021","unstructured":"Zhong X, Ouyang C, Liang W, Dai C, Zhang W. (2R,6R)-hydroxynorketamine alleviates electroconvulsive shock-induced learning impairment by inhibiting autophagy. Neuropsychiatr Dis Treat.2021;17:297\u2013304.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"1673_CR35","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41380-018-0083-8","volume":"24","author":"NH Wray","year":"2019","unstructured":"Wray NH, Schappi JM, Singh H, Senese NB, Rasenick MM. NMDAR-independent, cAMP-dependent antidepressant actions of ketamine. Mol Psychiatry. 2019;24:1833\u201343.","journal-title":"Mol Psychiatry"},{"key":"1673_CR36","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/WNR.0000000000001131","volume":"29","author":"G Collo","year":"2018","unstructured":"Collo G, Cavalleri L, Chiamulera C, Merlo Pich E. (2R,6R)-Hydroxynorketamine promotes dendrite outgrowth in human inducible pluripotent stem cell-derived neurons through AMPA receptor with timing and exposure compatible with ketamine infusion pharmacokinetics in humans. Neuroreport. 2018;29:1425\u201330.","journal-title":"Neuroreport."},{"key":"1673_CR37","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/mp.2017.239","volume":"23","author":"N Yao","year":"2018","unstructured":"Yao N, Skiteva O, Zhang X, Svenningsson P, Chergui K. Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit. Mol Psychiatry. 2018;23:2066\u201377.","journal-title":"Mol Psychiatry"},{"key":"1673_CR38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.neuropharm.2019.04.019","volume":"153","author":"CL Shaffer","year":"2019","unstructured":"Shaffer CL, Dutra JK, Tseng WC, Weber ML, Bogart LJ, Hales K, et al. Pharmacological evaluation of clinically relevant concentrations of (2R,6R)-hydroxynorketamine. Neuropharmacology. 2019;153:73\u201381.","journal-title":"Neuropharmacology."},{"key":"1673_CR39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/rapm-2018-000013","volume":"44","author":"JS Kroin","year":"2019","unstructured":"Kroin JS, Das V, Moric M, Buvanendran A. Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain. Reg Anesth Pain Med. 2019;44:111\u20137.","journal-title":"Reg Anesth Pain Med"},{"key":"1673_CR40","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41386-020-0663-6","volume":"45","author":"CA Farmer","year":"2020","unstructured":"Farmer CA, Gilbert JR, Moaddel R, George J, Adeojo L, Lovett J, et al. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology. 2020;45:1398\u2013404.","journal-title":"Neuropsychopharmacology."},{"key":"1673_CR41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jpsychires.2019.08.005","volume":"117","author":"MF Grunebaum","year":"2019","unstructured":"Grunebaum MF, Galfalvy HC, Choo TH, Parris MS, Burke AK, Suckow RF, et al. Ketamine metabolite pilot study in a suicidal depression trial. J Psychiatr Res. 2019;117:129\u201334.","journal-title":"J Psychiatr Res"},{"key":"1673_CR42","unstructured":"Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04711005?term=%28R%29-ketamine&draw=3&rank=40. Accessed November 2021."},{"key":"1673_CR43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/FBP.0000000000000014","volume":"25","author":"TM Hillhouse","year":"2014","unstructured":"Hillhouse TM, Porter JH. Ketamine, but not MK-801, produces antidepressant-like effects in rats responding on a differential-reinforcement-of-low-rate operant schedule. Behav Pharm. 2014;25:80\u201391.","journal-title":"Behav Pharm"},{"key":"1673_CR44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/ddr.21228","volume":"75","author":"TM Hillhouse","year":"2014","unstructured":"Hillhouse TM, Porte JH, Negus SS. Comparison of antidepressant-like and abuse-related effects of phencyclidine in rats. Drug Dev Res. 2014;75:479\u201388.","journal-title":"Drug Dev Res"},{"key":"1673_CR45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40263-021-00816-x","volume":"35","author":"ID Henter","year":"2021","unstructured":"Henter ID, Park LT, Zarate CA. Novel glutamatergic modulators for the treatment of mood disorders: current status. CNS Drugs. 2021;35:527\u201343.","journal-title":"CNS Drugs"},{"key":"1673_CR46","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejphar.2012.11.023","volume":"698","author":"R Moaddel","year":"2013","unstructured":"Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, et al. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in \u03b17 nicotinic acetylcholine receptors. Eur J Pharm. 2013;698:228\u201334.","journal-title":"Eur J Pharm"},{"key":"1673_CR47","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1021\/acs.orglett.7b02177","volume":"19","author":"PJ Morris","year":"2017","unstructured":"Morris PJ, Moaddel R, Zanos P, Moore CE, Gould T, Zarate CA, et al. Synthesis and N-Methyl- d -aspartate (NMDA) receptor activity of ketamine metabolites. Org Lett. 2017;19:4572\u20135.","journal-title":"Org Lett"},{"key":"1673_CR48","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1021\/acschemneuro.0c00741","volume":"12","author":"TT Joseph","year":"2021","unstructured":"Joseph TT, Bu W, Lin W, Zoubak L, Yeliseev A. Liu R, et al. Ketamine Metabolite (2 R,6 R)-Hydroxynorketamine Interacts with \u03bc and \u03ba Opioid Receptors. ACS Chem Neurosci. 2021;12:1487\u201397.","journal-title":"ACS Chem Neurosci"},{"key":"1673_CR49","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175:1205\u201315.","journal-title":"Am J Psychiatry"},{"key":"1673_CR50","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","volume":"24","author":"NR Williams","year":"2019","unstructured":"Williams NR, Heifets BD, Bentzley BS, Blasey C, Sudheimer KD, Hawkins J, et al. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. Mol Psychiatry. 2019;24:1779\u201386.","journal-title":"Mol Psychiatry"},{"key":"1673_CR51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1523\/JNEUROSCI.3481-08.2009","volume":"29","author":"X Chen","year":"2009","unstructured":"Chen X, Shu S, Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci. 2009;29:600\u20139.","journal-title":"J Neurosci"},{"key":"1673_CR52","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1021\/cb300296m","volume":"8","author":"AR Shepard","year":"2013","unstructured":"Shepard AR, Conrow RE, Pang IH, Jacobson N, Rezwan M, Rutschmann K, et al. Identification of PDE6D as a molecular target of anecortave acetate via a methotrexate-anchored yeast three-hybrid screen. ACS Chem Biol. 2013;8:549\u201358.","journal-title":"ACS Chem Biol"},{"key":"1673_CR53","doi-asserted-by":"crossref","first-page":"106993","DOI":"10.1016\/j.ntt.2021.106993","volume":"87","author":"PJ Morris","year":"2021","unstructured":"Morris PJ, Burke RD, Sharma AK, Lynch DC, Lemke-Boutcher LE, Mathew S, et al. A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. Neurotoxicol Teratol. 2021;87:106993.","journal-title":"Neurotoxicol Teratol"},{"key":"1673_CR54","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/bms.1200081103","volume":"8","author":"JD Adams","year":"1981","unstructured":"Adams JD, Baillie TA, Trevor AJ, Castagnoli N. Studies on the biotransformation of ketamine 1\u2014Identification of metabolites produced in vitro from rat liver microsomal preparations. Biol Mass Spectrom. 1981;8:527\u201338.","journal-title":"Biol Mass Spectrom"},{"key":"1673_CR55","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/dmd.30.7.853","volume":"30","author":"Y Hijazi","year":"2002","unstructured":"Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853\u20138.","journal-title":"Drug Metab Dispos"},{"key":"1673_CR56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"A Nair","year":"2016","unstructured":"Nair A, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7:27.","journal-title":"J Basic Clin Pharm"},{"key":"1673_CR57","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00213-010-2062-x","volume":"214","author":"MT De Luca","year":"2011","unstructured":"De Luca MT, Badiani A. Ketamine self-administration in the rat: evidence for a critical role of setting. Psychopharmacol. 2011;214:549\u201356.","journal-title":"Psychopharmacol"},{"key":"1673_CR58","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejphar.2012.11.023","volume":"698","author":"R Moaddel","year":"2013","unstructured":"Moaddel R, Abdrakhmanova G, Kozak J, Jozwiak K, Toll L, Jimenez L, et al. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in \u03b17 nicotinic acetylcholine receptors. Eur J Pharm. 2013;698:228\u201334.","journal-title":"Eur J Pharm"},{"key":"1673_CR59","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/nature22084","volume":"546","author":"K Suzuki","year":"2017","unstructured":"Suzuki K, Nosyreva E, Hunt KW, Kavalali ET, Monteggia LM. Effects of a ketamine metabolite on synaptic NMDAR function. Nature. 2017;546:E1\u2013E3.","journal-title":"Nature."},{"key":"1673_CR60","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/bcpt.12941","volume":"122","author":"TO Lilius","year":"2018","unstructured":"Lilius TO, Viisanen H, Jokinen V, Niemi M, Kalso EA, Rauhala PV. Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine. Basic Clin Pharm Toxicol. 2018;122:481\u20138.","journal-title":"Basic Clin Pharm Toxicol"},{"key":"1673_CR61","unstructured":"Li J, Chen FF, Chen XD, Zhou C. Inhibition of HCN1 channels by ketamine accounts for its antidepressant actions. J Sichuan Univ Medical Sci Ed. 2014;45:888\u201392, 932."},{"key":"1673_CR62","doi-asserted-by":"crossref","first-page":"7424","DOI":"10.1523\/JNEUROSCI.0936-11.2011","volume":"31","author":"AS Lewis","year":"2011","unstructured":"Lewis AS, Vaidya SP, Blaiss CA, Liu Z, Stoub TR, Brager DH, et al. Deletion of the hyperpolarization-activated cyclic nucleotide-gated channel auxiliary subunit TRIP8b impairs hippocampal Ih localization and function and promotes antidepressant behavior in mice. J Neurosci. 2011;31:7424\u201340.","journal-title":"J Neurosci"},{"key":"1673_CR63","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuron.2012.05.027","volume":"75","author":"CS Kim","year":"2012","unstructured":"Kim CS, Chang PY, Johnston D. Enhancement of dorsal hippocampal activity by knockdown of hcn1 channels leads to anxiolytic- and antidepressant-like behaviors. Neuron. 2012;75:503\u201316.","journal-title":"Neuron."},{"key":"1673_CR64","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/mp.2016.99","volume":"22","author":"Y Han","year":"2017","unstructured":"Han Y, Heuermann RJ, Lyman KA, Fisher D, Ismail QA, Chetkovich DM. HCN-channel dendritic targeting requires bipartite interaction with TRIP8b and regulates antidepressant-like behavioral effects. Mol Psychiatry. 2017;22:458\u201365.","journal-title":"Mol Psychiatry"},{"key":"1673_CR65","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1523\/JNEUROSCI.0177-16.2016","volume":"36","author":"AT Knoll","year":"2016","unstructured":"Knoll AT, Halladay LR, Holmes A, Levitt P. Quantitative trait loci and a novel genetic candidate for fear learning. J Neurosci. 2016;36:6258\u201368.","journal-title":"J Neurosci"},{"key":"1673_CR66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.116.235838","volume":"359","author":"A Can","year":"2016","unstructured":"Can A, Zanos P, Moaddel R, Kang HJ, Dossou KSS, Wainer IW, et al. Effects of ketamine and ketamine metabolites on evoked striatal dopamine release, dopamine receptors, and monoamine transporters. J Pharm Exp Ther. 2016;359:159\u201370.","journal-title":"J Pharm Exp Ther"},{"key":"1673_CR67","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.3389\/fphar.2019.01302","volume":"10","author":"MF Ho","year":"2019","unstructured":"Ho MF, Zhang C, Zhang L, Li H, Weinshilboum RM. Ketamine and active ketamine metabolites regulate STAT3 and the Type i interferon pathway in human microglia: Molecular mechanisms linked to the antidepressant effects of ketamine. Front Pharm. 2019;10:1302.","journal-title":"Front Pharm"},{"key":"1673_CR68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/j.1875-9114.1987.tb03496.x","volume":"7","author":"RW Sommi","year":"1987","unstructured":"Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin\u2010specific, second\u2010generation antidepressant. pharmacother. J Hum Pharmacol Drug Ther. 1987;7:1\u201314.","journal-title":"J Hum Pharmacol Drug Ther"},{"key":"1673_CR69","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/s41386-018-0084-y","volume":"43","author":"J Yamaguchi","year":"2018","unstructured":"Yamaguchi J, Toki H, Qu Y, Yang C, Koike H, Hashimoto K, et al. (2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice. Neuropsychopharmacology. 2018;43:1900.","journal-title":"Neuropsychopharmacology."},{"key":"1673_CR70","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","volume":"72","author":"CA Zarate","year":"2012","unstructured":"Zarate CA, Brutsche N, Laje G, Luckenbaugh DA, Venkata SLV, Ramamoorthy A, et al. Relationship of ketamine\u2019s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012;72:331\u20138.","journal-title":"Biol Psychiatry"},{"key":"1673_CR71","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/00498254.2012.685777","volume":"42","author":"Z Desta","year":"2012","unstructured":"Desta Z, Moaddel R, Ogburn ET, Xu C, Ramamoorthy A, Venkata SLV, et al. Stereoselective and regiospecific hydroxylation of ketamine and norketamine. Xenobiotica. 2012;42:1076\u201387.","journal-title":"Xenobiotica."},{"key":"1673_CR72","doi-asserted-by":"crossref","first-page":"108965","DOI":"10.1016\/j.neuropharm.2022.108965","volume":"208","author":"P Goswamee","year":"2022","unstructured":"Goswamee P, Rice R, Leggett E, Zhang F, Manicka S, Porter JH, et al. Effects of subanesthetic ketamine and (2R,6R) hydroxynorketamine on working memory and synaptic transmission in the nucleus reuniens in mice. Neuropharmacology. 2022;208:108965.","journal-title":"Neuropharmacology."},{"key":"1673_CR73","first-page":"1","volume":"8","author":"K Zhang","year":"2018","unstructured":"Zhang K, Fujita Y, Hashimoto K. Lack of metabolism in (R)-ketamine\u2019s antidepressant actions in a chronic social defeat stress model. Sci Rep. 2018;8:1\u20138.","journal-title":"Sci Rep"},{"key":"1673_CR74","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.biopsych.2017.12.007","volume":"84","author":"K Hashimoto","year":"2018","unstructured":"Hashimoto K, Shirayama Y. What are the causes for discrepancies of antidepressant actions of (2R,6R)-Hydroxynorketamine? Biol Psychiatry. 2018;84:e7\u2013e8.","journal-title":"Biol Psychiatry"},{"key":"1673_CR75","doi-asserted-by":"crossref","first-page":"111904","DOI":"10.1016\/j.bbr.2019.111904","volume":"368","author":"Z Xiong","year":"2019","unstructured":"Xiong Z, Fujita Y, Zhang K, Pu Y, Chang L, Ma M, et al. Beneficial effects of (R)-ketamine, but not its metabolite (2R,6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model. Behav Brain Res. 2019;368:111904.","journal-title":"Behav Brain Res"},{"key":"1673_CR76","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nmeth.2935","volume":"11","author":"RE Sorge","year":"2014","unstructured":"Sorge RE, Martin LJ, Isbester KA, Sotocinal SG, Rosen S, Tuttle AH, et al. Olfactory exposure to males, including men, causes stress and related analgesia in rodents. Nat Methods. 2014;11:629\u201332.","journal-title":"Nat Methods"},{"key":"1673_CR77","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/laban.1223","volume":"46","author":"JS Mogil","year":"2017","unstructured":"Mogil JS. Laboratory environmental factors and pain behavior: The relevance of unknown unknowns to reproducibility and translation. Lab Anim. 2017;46:136\u201341.","journal-title":"Lab Anim"},{"key":"1673_CR78","doi-asserted-by":"crossref","unstructured":"Georgiou P, Zanos P, Mou T-CM, An X, Gerhard DM, Dryanovski DI, et al. Experimenter sex modulates mouse biobehavioural and pharmacological responses. BioRxiv. 2022:2022.01.09.475572.","DOI":"10.1101\/2022.01.09.475572"},{"key":"1673_CR79","doi-asserted-by":"crossref","first-page":"10576","DOI":"10.1074\/jbc.M609695200","volume":"282","author":"LI Jiang","year":"2007","unstructured":"Jiang LI, Collins J, Davis R, Lin K-M, DeCamp D, Roach T, et al. Use of a cAMP BRET Sensor to Characterize a Novel Regulation of cAMP by the Sphingosine 1-Phosphate\/G13 Pathway. J Biol Chem. 2007;282:10576.","journal-title":"J Biol Chem"},{"key":"1673_CR80","doi-asserted-by":"crossref","unstructured":"Cai N-S, Quiroz C, Bonaventura J, Bonifazi A, Cole TO, Purks J, et al. Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids. J Clin Invest. 2019;129:2730\u201344.","DOI":"10.1172\/JCI126912"},{"key":"1673_CR81","doi-asserted-by":"publisher","unstructured":"Bonaventura J, Eldridge MAG, Hu F, Gomez JL, Sanchez-Soto M, Abramyan AM, et al. High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nat Commun. 2019;10:4627. https:\/\/doi.org\/10.1038\/s41467-019-12236-z.","DOI":"10.1038\/s41467-019-12236-z"},{"key":"1673_CR82","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jneumeth.2006.01.027","volume":"155","author":"WK Schiffer","year":"2006","unstructured":"Schiffer WK, Mirrione MM, Biegon A, Alexoff DL, Patel V, Dewey SL. Serial microPET measures of the metabolic reaction to a microdialysis probe implant. J Neurosci Methods. 2006;155:272\u201384.","journal-title":"J Neurosci Methods"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01673-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01673-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01673-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T10:44:13Z","timestamp":1680864253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-022-01673-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1673"],"URL":"https:\/\/doi.org\/10.1038\/s41380-022-01673-w","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"28 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation. CZ and RM are co-inventors on a patent for the use of (2R,6R)-HNK, (S)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (R,S)-ketamine metabolites in the treatment of depression and neuropathic pain. PZ, RM, PM, CJT, CAZ and TDG are co-inventors on a patent application for the use of (2R,6R)-HNK and (2S,6S)-HNK in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders, and on a patent on the crystal forms and methods of synthesis of (2R,6R)-HNK and (2S,6S)-HNK. PM and CJT are co-inventors on a patent application for the salts of (2R,6R)-HNK, their crystal forms, and methods of making the same and the process for synthesis and purification of (2R,6R)-HNK. RM, PM, CAZ, and CT have assigned their patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government. PZ and TDG have assigned their patent rights to the University of Maryland Baltimore but will share a percentage of any royalties that may be received by the University of Maryland Baltimore. MM has received research funding from AstraZeneca, Redpin Therapeutics and Attune Neurosciences. All other authors declare no conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}